ERBB2 and gastric cancer: Nevertheless, the success obtained with anti-HER2 therapies [1,6,21], the use of immune checkpoint inhibitors in some types of GC, and new molecular markers open the door to a combination of classical chemotherapy, immunotherapy and molecular therapy, which could improve outcomes and survival [9,12,19,25,31,35].